

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

SCHUPPAN et al.

Serial No. TO BE ASSIGNED

Filed: WITH DIVISIONAL APPLN.

For: USE OF ENDOTHELIN INHIBITORS FOR TREATMENT OR PREVENTION OF
FIBROTIC DISORDERS

Art Unit: 1644

Examiner: Ewoldt

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination of this divisional application, please enter the following
amendment.

204710-CEH001


REMARKS

Claims 4-12 are pending.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF



Jason D. Voight
Reg. No. 42,205

1101 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100


JDV/kas

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please cancel claims 1-3.

Please add the following claims.

7. (new) A method for treating or preventing a fibrotic disorder, said method comprising administering an effective amount of an endothelin inhibitor to a mammal.
8. (new) The method of claim 7, wherein the disorder is a fibrotic disorder of the liver.
9. (new) The method of claim 7, wherein the disorder is fibrosis or cirrhosis.
10. (new) The method of claim 7, wherein the endothelin inhibitor is an endothelin receptor antagonist.
11. (new) The method of claim 7, wherein the endothelin inhibitor is a specific ETA receptor antagonist.
12. (new) The method of claim 7, wherein the endothelin inhibitor is a compound of formula I



where


R¹ and R² independently are C₁-C₂-alkyl or C₁-C₂-alkoxy,

R³ is C₁-C₂-alkyl which may carry a phenyl which may carry up to 2 identical or different C₁-C₂-alkoxy radicals, and

Z is oxygen or a single bond.

COPY OF ALL CLAIMS

4. Pharmaceutical composition for prophylaxis or treatment of fibrotic disorders comprising as effective compound an endothelin inhibitor.
5. Pharmaceutical compositions according to claim 4 where the endothelin inhibitor is an endothelin receptor antagonist.
6. Pharmaceutical compositions according to claim 4 where the endothelin inhibitor is a specific ETA receptor antagonist.
7. (new) A method for treating or preventing a fibrotic disorder, said method comprising administering an effective amount of an endothelin inhibitor to a mammal.
8. (new) The method of claim 7, wherein the disorder is a fibrotic disorder of the liver.
9. (new) The method of claim 7, wherein the disorder is fibrosis or cirrhosis.
10. (new) The method of claim 7, wherein the endothelin inhibitor is an endothelin receptor antagonist.
11. (new) The method of claim 7, wherein the endothelin inhibitor is a specific ETA receptor antagonist.
12. (new) The method of claim 7, wherein the endothelin inhibitor is a compound of formula I



where

R^1 and R^2 independently are C_1 - C_2 -alkyl or C_1 - C_2 -alkoxy,

R^3 is C_1 - C_2 -alkyl which may carry a phenyl which may carry up to 2 identical or different

C_1 - C_2 -alkoxy radicals, and

Z is oxygen or a single bond.